Literature DB >> 12364433

Prenatal diagnosis of sex differentiation disorders: the role of fetal ultrasound.

Orit Pinhas-Hamiel1, Yaron Zalel, Eric Smith, Ram Mazkereth, Ayala Aviram, Shlomo Lipitz, Reuven Achiron.   

Abstract

We describe our experience with prenatal diagnosis of sex differentiation disorders, with focus on the role of ultrasound scans for coherent assessment of prenatal diagnosis. Over a 5-yr period all cases suspected of sexual ambiguity based on abnormal ultrasonographic scans (US) or US/genotype US discrepancy were evaluated prenatally by three modalities: 1) repeated fetal US; 2) genetic studies, primarily karyotype and fluorescence in situ hybridization analysis of sex-determining region on the Y gene (SRY); and 3) hormonal assays of amniotic fluid. Of approximately 10,000 gestations, 16 fetuses underwent prenatal evaluation. Twelve were referred because of an abnormal US and 4 because of genotype-phenotype discrepancy. Five fetuses were diagnosed with female pseudohermaphroditism (21-hydroxylase deficiency in 3 and urorectal septum malformation sequence in 2). Four fetuses were diagnosed with male pseudohermaphroditism (1 with steroid sulfatase deficiency, 1 with presumed camptomelic dysplasia, and 2 undetermined). Five cases had chromosomal abnormalities, and 2 had 46,XX+SRY sex reversal. In all genetic females the uterus was observed on US. In 11 cases initial US scan was performed at 13-15 wk; in 7 of 11, although the initial scan was normal, a repeated scan later in gestation revealed an abnormality. Repeated US scans performed at 13-15 and 22-24 wk gestation are a helpful tool in prenatal diagnosis of sex differentiation disorders. Our data suggest that both size and structure anomalies of the reproductive structures may evolve throughout pregnancy, and that they represent a developmental biological process rather than a single nonprogressive pathological event. US scan after approximately 19 wk enables detection of the uterus and provides pivotal information in cases of ambiguity. If the uterus appears normal, the most likely diagnosis is a virilized karyotypic female. Prenatal diagnosis allows for early parental counseling and anticipation of medical management postnatally.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12364433     DOI: 10.1210/jc.2001-011034

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  6 in total

1.  Prenatal diagnosis of 46, XX male fetus.

Authors:  M J Trujillo-Tiebas; C González-González; I Lorda-Sánchez; M E Querejeta; C Ayuso; C Ramos
Journal:  J Assist Reprod Genet       Date:  2006-05-25       Impact factor: 3.412

Review 2.  Disorders of sex development: effect of molecular diagnostics.

Authors:  John C Achermann; Sorahia Domenice; Tania A S S Bachega; Mirian Y Nishi; Berenice B Mendonca
Journal:  Nat Rev Endocrinol       Date:  2015-05-05       Impact factor: 43.330

Review 3.  Prostate gland development and adrenal tumor in a female with congenital adrenal hyperplasia: a case report and review from radiology perspective.

Authors:  Benjamin Fang; Francis Cho; Wendy Lam
Journal:  J Radiol Case Rep       Date:  2013-12-01

4.  Antenatal Diagnosis of Dizygotic, Monochorionic Twins Following IVF/ICSI.

Authors:  P Korsun; M Bals-Pratsch; O Ortmann; S Markus; U Germer
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-06       Impact factor: 2.915

5.  Disorders of sexual development with XY karyotype and female phenotype: clinical findings and genetic background in a cohort from a single centre.

Authors:  G Costagliola; M Cosci O di Coscio; B Masini; F Baldinotti; M A Caligo; N Tyutyusheva; M R Sessa; D Peroni; S Bertelloni
Journal:  J Endocrinol Invest       Date:  2020-05-06       Impact factor: 4.256

Review 6.  Disorders/Differences of Sex Development Presenting in the Newborn With 46,XY Karyotype.

Authors:  Silvano Bertelloni; Nina Tyutyusheva; Margherita Valiani; Franco D'Alberton; Fulvia Baldinotti; Maria Adelaide Caligo; Giampiero I Baroncelli; Diego G Peroni
Journal:  Front Pediatr       Date:  2021-04-22       Impact factor: 3.418

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.